Thalassemia Treatment Market 2027 By Treatment Type | The Insight Partners

Thalassemia Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Treatment Type (blood transfusion, chelating therapy, bone marrow transplant, others)

Report Code: TIPRE00011968 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Thalassemia is a genetic disorder related to blood. In this disease, patient's body is not able to produce normal hemoglobin and manufactures a huge number of abnormal red blood cells, which are continuously destroyed. As a result, an individual becomes anemic.

MARKET DYNAMICS

The thalassemia treatment market is witnessing stupendous growth avenues due to significant growth in the number of blood transfusion and chelation therapy treatments. Moreover, increased number of bone marrow transplants, rise in number of spleen surgeries, and increased investments in research and development activities are some of the key factors stimulating the growth of the global thalassemia treatment market.

MARKET SCOPE

The "Thalassemia Treatment Market Analysis to 2027" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of thalassemia treatment market with detailed market segmentation by treatment type. The thalassemia treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in thalassemia treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The thalassemia treatment market is segmented on the basis of treatment type. Based on treatment type, the market is segmented as blood transfusion, chelating therapy, bone marrow transplant, and others.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the thalassemia treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The thalassemia treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting thalassemia treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the thalassemia treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the thalassemia treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from thalassemia treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for thalassemia treatment in the global market. Below mentioned is the list of few companies engaged in the thalassemia treatment market.

The report also includes the profiles of key players in thalassemia treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Acceleron Pharma, Inc.
  •   bluebird bio, Inc.
  •   Celgene Corporation
  •   Novartis AG
  •   Shire plc (Takeda Pharmaceuticals)


The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Thalassemia Treatment Market - By Treatment Type
1.3.2 Thalassemia Treatment Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. THALASSEMIA TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. THALASSEMIA TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. THALASSEMIA TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. THALASSEMIA TREATMENT - GLOBAL MARKET OVERVIEW
6.2. THALASSEMIA TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. THALASSEMIA TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
7.1. OVERVIEW
7.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
7.3. BLOOD TRANSFUSION
7.3.1. Overview
7.3.2. blood transfusion Market Forecast and Analysis
7.4. CHELATING THERAPY
7.4.1. Overview
7.4.2. chelating therapy Market Forecast and Analysis
7.5. BONE MARROW TRANSPLANT
7.5.1. Overview
7.5.2. bone marrow transplant Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. others Market Forecast and Analysis
8. THALASSEMIA TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Thalassemia Treatment Market Overview
8.1.2 North America Thalassemia Treatment Market Forecasts and Analysis
8.1.3 North America Thalassemia Treatment Market Forecasts and Analysis - By Treatment Type
8.1.4 North America Thalassemia Treatment Market Forecasts and Analysis - By Countries
8.1.4.1 United States Thalassemia Treatment Market
8.1.4.1.1 United States Thalassemia Treatment Market by Treatment Type
8.1.4.2 Canada Thalassemia Treatment Market
8.1.4.2.1 Canada Thalassemia Treatment Market by Treatment Type
8.1.4.3 Mexico Thalassemia Treatment Market
8.1.4.3.1 Mexico Thalassemia Treatment Market by Treatment Type
8.2. EUROPE
8.2.1 Europe Thalassemia Treatment Market Overview
8.2.2 Europe Thalassemia Treatment Market Forecasts and Analysis
8.2.3 Europe Thalassemia Treatment Market Forecasts and Analysis - By Treatment Type
8.2.4 Europe Thalassemia Treatment Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Thalassemia Treatment Market
8.2.4.1.1 Germany Thalassemia Treatment Market by Treatment Type
8.2.4.2 France Thalassemia Treatment Market
8.2.4.2.1 France Thalassemia Treatment Market by Treatment Type
8.2.4.3 Italy Thalassemia Treatment Market
8.2.4.3.1 Italy Thalassemia Treatment Market by Treatment Type
8.2.4.4 Spain Thalassemia Treatment Market
8.2.4.4.1 Spain Thalassemia Treatment Market by Treatment Type
8.2.4.5 United Kingdom Thalassemia Treatment Market
8.2.4.5.1 United Kingdom Thalassemia Treatment Market by Treatment Type
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Thalassemia Treatment Market Overview
8.3.2 Asia-Pacific Thalassemia Treatment Market Forecasts and Analysis
8.3.3 Asia-Pacific Thalassemia Treatment Market Forecasts and Analysis - By Treatment Type
8.3.4 Asia-Pacific Thalassemia Treatment Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Thalassemia Treatment Market
8.3.4.1.1 Australia Thalassemia Treatment Market by Treatment Type
8.3.4.2 China Thalassemia Treatment Market
8.3.4.2.1 China Thalassemia Treatment Market by Treatment Type
8.3.4.3 India Thalassemia Treatment Market
8.3.4.3.1 India Thalassemia Treatment Market by Treatment Type
8.3.4.4 Japan Thalassemia Treatment Market
8.3.4.4.1 Japan Thalassemia Treatment Market by Treatment Type
8.3.4.5 South Korea Thalassemia Treatment Market
8.3.4.5.1 South Korea Thalassemia Treatment Market by Treatment Type
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Thalassemia Treatment Market Overview
8.4.2 Middle East and Africa Thalassemia Treatment Market Forecasts and Analysis
8.4.3 Middle East and Africa Thalassemia Treatment Market Forecasts and Analysis - By Treatment Type
8.4.4 Middle East and Africa Thalassemia Treatment Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Thalassemia Treatment Market
8.4.4.1.1 South Africa Thalassemia Treatment Market by Treatment Type
8.4.4.2 Saudi Arabia Thalassemia Treatment Market
8.4.4.2.1 Saudi Arabia Thalassemia Treatment Market by Treatment Type
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Thalassemia Treatment Market Overview
8.5.2 South and Central America Thalassemia Treatment Market Forecasts and Analysis
8.5.3 South and Central America Thalassemia Treatment Market Forecasts and Analysis - By Treatment Type
8.5.4 South and Central America Thalassemia Treatment Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Thalassemia Treatment Market
8.5.4.1.1 Brazil Thalassemia Treatment Market by Treatment Type
8.5.4.2 Argentina Thalassemia Treatment Market
8.5.4.2.1 Argentina Thalassemia Treatment Market by Treatment Type
9. IMPACT OF COVID-19 PANDEMIC ON GLOBAL THALASSEMIA TREATMENT MARKET
9.1 North America
9.2 Europe
9.3 Asia-Pacific
9.4 Rest of the World
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. THALASSEMIA TREATMENT MARKET, KEY COMPANY PROFILES
11.1. ACCELERON PHARMA, INC.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. BLUEBIRD BIO, INC.
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. CELGENE CORPORATION
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. NOVARTIS AG
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. SHIRE PLC (TAKEDA PHARMACEUTICALS)
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. Acceleron Pharma, Inc.
2. bluebird bio, Inc.
3. Celgene Corporation
4. Novartis AG
5. Shire plc (Takeda Pharmaceuticals)
TIPRE00011968
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking